Search

Merck & Co Inc.

Затворен

СекторЗдравеопазване

147.78 -0.31

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

147.68

Максимум

148.4

Ключови измерители

By Trading Economics

Приходи

2.9B

-1.3B

Продажби

321M

17B

P/E

Средно за сектора

121.5

57.366

EPS

-0.13

Дивидентна доходност

2.18

Марж на печалбата

-8.051

Служители

73,000

EBITDA

3.4B

1.4B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+3.56% upside

Дивиденти

By Acuity

Дивидентна доходност

Средно за сектора

2.18%

2.16%

Следващи печалби

29.10.2026 г.

Следваща дата на дивидент

7.10.2026 г.

Следваща дата на екс-дивидент

15.09.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

64B

372B

Предишно отваряне

148.09

Предишно затваряне

147.78

Настроения в новините

By Acuity

46%

54%

112 / 340 Класиране в Healthcare

Merck & Co Inc. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.08.2026 г., 23:01 ч. UTC

Merck & Co Inc shares are higher in after-market trading, supported by rising Treasury yields and trading above their 20-day moving average.

27.08.2026 г., 23:01 ч. UTC

Merck & Co Inc. shares are higher in after-market trading, reflecting routine performance despite three consecutive lower sessions. The stock remains above its 20-day moving average.

26.08.2026 г., 23:11 ч. UTC

Merck & Co Inc is higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

25.08.2026 г., 23:06 ч. UTC

Social Media

Merck & Co Inc reached all-time highs in after-market trading, gaining over $6 amid positive social media sentiment and broader market dynamics.

24.08.2026 г., 23:16 ч. UTC

Merck & Co Inc shares are higher in after-market trading, showing stable performance since Monday's close. The stock remains above its 20-day moving average.

21.08.2026 г., 19:31 ч. UTC

News
Social Media

Merck & Co Inc shares are higher today as Goldman Sachs and Morgan Stanley upgraded their ratings and raised price targets, citing confidence in cancer treatments.

20.08.2026 г., 19:31 ч. UTC

News
Social Media
Event

Merck & Co Inc shares are lower today following downgrades from RBC Capital and UBS, with both firms setting a price target of $150.

19.08.2026 г., 23:41 ч. UTC

Event
Social Media

Merck & Co Inc shares declined in after-market trading despite positive Phase 3 trial results for its mRNA-based therapy combined with KEYTRUDA.

17.08.2026 г., 19:36 ч. UTC

News

Merck & Co Inc shares are higher during Monday's session, reflecting a slight cumulative return since Friday's close amid rising long-term Treasury yields.

15.08.2026 г., 00:01 ч. UTC

Merck & Co Inc shares are lower in after-market hours following notable volatility during the session, despite mixed global market performance.

14.08.2026 г., 23:21 ч. UTC

Merck & Co Inc shares are lower in after-market trading following a decline in U.S. retail sales for July, raising concerns about consumer demand.

13.08.2026 г., 23:06 ч. UTC

Merck & Co Inc. shares were roughly flat in after-market hours, remaining above their 20-day moving average after three consecutive sessions of higher finishes.

12.08.2026 г., 19:56 ч. UTC

News

Daiwa Capital upgraded Merck to Outperform, raising the price target to $143. The stock remains higher since Tuesday's close amid positive FDA news.

11.08.2026 г., 19:36 ч. UTC

News

Merck & Co. shares are lower today despite Argus Research maintaining a Buy rating and raising the price target to $145.

10.08.2026 г., 19:36 ч. UTC

Social Media
News

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.

7.08.2026 г., 22:06 ч. UTC

Merck & Co Inc. shares were roughly flat in after-market hours. This stability aligns with broader positive sentiment on Wall Street amid easing interest rate concerns.

6.08.2026 г., 23:01 ч. UTC

Event

Merck & Co Inc shares are trading lower in after-market hours following the FDA's acceptance of a supplemental application for ENFLONSIA™.

5.08.2026 г., 19:43 ч. UTC

News
Social Media

Merck & Co. received Health Canada approval for Keytruda, yet shares are lower amid mixed market sentiment following disappointing ADP employment data.

4.08.2026 г., 23:26 ч. UTC

News

Merck & Co Inc reported a Q2 net loss of $1.3 billion. Shares are higher in after-market hours amid broader market gains from oil supply negotiations.

3.08.2026 г., 20:03 ч. UTC

News
Social Media

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

31.07.2026 г., 23:16 ч. UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

30.07.2026 г., 20:09 ч. UTC

Merck & Co Inc shares are declining, with no specific news identified. Broader market volatility is influenced by mixed economic signals and jobless claims.

29.07.2026 г., 23:41 ч. UTC

Merck & Co Inc shares are lower in after-market hours, driven by weakness in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

28.07.2026 г., 23:01 ч. UTC

Merck & Co Inc shares are higher in after-market hours, maintaining stability above the 20-day moving average and near the upper end of their one-month range.

27.07.2026 г., 20:06 ч. UTC

Social Media

Merck & Co Inc shares are lower, testing the $132 level amid broader market declines and declining oil prices impacting Treasury yields ahead of the Fed meeting.

24.07.2026 г., 18:56 ч. UTC

News
Social Media

Merck & Co Inc. announced a strategy to enhance access to its HIV prevention drug Alimatravir across 129 countries, boosting shares during Friday's session.

22.07.2026 г., 19:46 ч. UTC

Social Media

Merck & Co Inc shares are higher, supported by strong contract performance valued at $1,000. The stock remains near its one-month high amid broader market challenges.

21.07.2026 г., 19:56 ч. UTC

News
Social Media

Merck & Co. Inc. shares are rising following positive Phase 3 trial results for its once-weekly oral HIV treatment regimen, islatravir and lenacapavir.

20.07.2026 г., 20:02 ч. UTC

Social Media

Merck & Co. shares are lower as the pharmaceutical sector faces pressure. The company plans to price Lipfendra at $10.50 per day.

Сравнение с други в отрасъла

Ценова промяна

Merck & Co Inc. Прогноза

Ценова цел

By TipRanks

3.56% нагоре

12-месечна прогноза

Среден 153.63 USD  3.56%

Висок 180 USD

Нисък 105 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за Merck & Co Inc. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

17 ratings

13

Купи

4

Задържане

0

Продай

Настроение

By Acuity

112 / 340 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
help-icon Live chat